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Abstract
The differential diagnosis of differences or disorders of sex development (DSD) belongs to the most complex fields 
in medicine. It requires a multidisciplinary team conducting a synoptic and complementary approach consisting 
of thorough clinical, hormonal and genetic workups. This position paper of EU COST (European Cooperation in 
Science and Technology) Action BM1303 ‘DSDnet’ was written by leading experts in the field and focuses on current 
best practice in genetic diagnosis in DSD patients. Ascertainment of the karyotpye defines one of the three major 
diagnostic DSD subclasses and is therefore the mandatory initial step. Subsequently, further analyses comprise 
molecular studies of monogenic DSD causes or analysis of copy number variations (CNV) or both. Panels of candidate 
genes provide rapid and reliable results. Whole exome and genome sequencing (WES and WGS) represent valuable 
methodological developments that are currently in the transition from basic science to clinical routine service in the 
field of DSD. However, in addition to covering known DSD candidate genes, WES and WGS help to identify novel 
genetic causes for DSD. Diagnostic interpretation must be performed with utmost caution and needs careful scientific 
validation in each DSD case.
Introduction
Differences or disorders of sex development (DSD) arise 
during embryonic and foetal development. They may be 
caused by (1) numerical or structural variations in sex 
chromosomes, (2) variations in genes involved in gonadal 
and/or genital development (leading to inactivation 
or activation), (3) disorders in gonadal and/or adrenal 
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steroidogenesis (1), (4) maternal factors (endogenous or 
exogenous) or (5) endocrine disruptors that can interfere 
with genital development (2, 3). A final, yet putative 
category would consist of cases resulting from epigenetic 
changes that are predicted to disrupt gene expression in 
the foetal period. Many causes are genetically determined 
and should be analysed when a genetic cause for a DSD 
is sought (4, 5, 6, 7). Reaching a molecular diagnosis is 
important as it may inform patient management in 
relation to possible gender development, assessment 
of adrenal and gonadal function, gonadal cancer risk, 
associated morbidity as well as long-term outcomes. 
Determining the aetiology is often useful for families, as 
it provides information about risk of recurrence (8, 9, 10).
This paper proposes practical recommendations for 
the approach to a genetic diagnosis of DSD, taking into 
account the clinical and biochemical phenotypes, if 
available, and the rapidly developing genetic technologies 
that continuously improve the diagnostic yield in 
this heterogeneous group of conditions. Diagnosis of 
DSD belongs to the most complex fields in medicine 
and requires an integrated multidisciplinary approach 
consisting in a synoptic view of clinical phenotype, 
biochemical (hormonal) constellation and molecular 
datasets. This position paper presents current best practice 
in the molecular genetic diagnosis of DSD and is the result 
of a truly Europe-wide concerted action of leading DSD 
specialists within EU COST Action BM 1303 ‘DSDnet’.
General approach to the genetic diagnosis 
of DSD
If DSD is considered as all types of atypical genitalia at 
birth together with all discordances among chromosomal, 
gonadal and genital sexes, the prevalence of DSD reaches 
about 5 per 1000 births, with 73% of them being boys with 
hypospadias (11). Among children with atypical genitalia, 
75% will have a 46,XY karyotype, 10–15% a 46,XX and the 
remainder will have structural or numerical anomalies of 
the sex chromosomes (12). The most frequent autosomal 
recessive condition associated with monogenic DSD in 
individuals with 46,XX karyotype is congenital adrenal 
hyperplasia (CAH) due to 21-hydroxylase deficiency. It 
accounts for approximately 90–95% of 46,XX individuals 
(13). Other well-characterised monogenic 46,XX DSDs are 
extremely rare (see list in Table  1), and their molecular 
diagnosis has long been challenging.
Data collected between 1966 and 2014 showed that 
the prevalence of females with a 46,XY karyotype is 
6.4/100 000 among live-born females, with 4.1/100 000 
associated with androgen insensitivity (AIS) and 
1.5/100  000 having a form of gonadal dysgenesis (14). 
Even if clinical and biochemical investigations may 
adequately orient the molecular diagnosis, success in 
reaching a molecular diagnosis in 46,XY DSD is relatively 
low (5). This is most likely due to the heterogeneous 
clinical and hormonal presentation of many DSDs, the 
large number of known DSD-related genes (Table  1) 
with often low genotype–phenotype correlation and the 
increasing evidence that a significant proportion of the 
underlying pathogenesis may be multifactorial (15, 16). 
Newer molecular genetic diagnostic strategies employing 
high-throughput sequencing (HTS) screen large panels 
of known DSD-related genes simultaneously, thereby 
improving diagnostic yield. Further investigation by 
whole exome (WES) (17) or genome (WGS) sequencing 
may identify novel genes involved in the development of 
the phenotype. A comprehensive list of genes known to 
be involved in human 46,XY and 46,XX DSD (including 
gonadal dysgenesis, primary and secondary gonadal 
insufficiency, disordered steroidogenesis, androgen 
resistance, isolated urogenital anomalies and syndromic 
conditions associated with ambiguous genitalia) is reported 
along with their chromosomal locations: it amounts to 
62 genes in 46,XY and 61 in 46,XX (9). However, with 
further advance in knowledge about embryonic and foetal 
development, it is likely that more candidate genes for 
adrenal and reproductive disorders will be identified in 
the near future (18).
A diagnosis of DSD may be requested prenatally, in a 
neonate, infant or in a prepubertal child or adolescent/
adult person either because there is a family history of 
DSD or because the phenotype suggests the presence 
of DSD. Recommendations regarding clinical care are 
essential components of an individualised care plan and 
comprise: informed consent, diagnostic investigations, 
information and psychological support to patients and 
parents, transition, multidisciplinary care in adulthood, 
data collection across ages for the assessment of genital 
status, urological and gynaecological follow-up, somatic 
assessment, assessment of psychological outcomes and 
quality of life (19). Also, steroid hormone diagnostics 
(analytical methods and matrices, harmonisation of 
laboratory tests and steroid analysis in conditions 
associated with DSD) are essential part of DSD evaluation 
(20). Such recommendations have already been published 
as Consensus Statements by COST Action BM1303 
working groups. The multidisciplinary team (paediatric 
or adult endocrinology, urology or gynaecology, clinical 
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Table 1 Genes involved in monogenic disorders/different sex development (DSD).
Clinical diagnosis Gene (locus) OMIM (inheritance) (additional phenotype)
1. 46,XX with disorders of gonadal development: gonadal dysgenesis, ovotesticular DSD, testicular DSD
 Gonadal dysgenesis BMP15 (Xp11.22) 300510 (D)
 Testicular DSD FGF9 (13q12.11) 600921 (AD:dup) (single case description)
 Gonadal dysgenesis FOXL2 (3q22.3) 608996 (AD) (blepharophimosis, epicanthus inversus and 
ptosis, types I and II)
 Testicular DSD NR2F2 (15q26.2) 615779 (AD) (congenital heart defects, congenital 
diaphragmatic hernia, blepharo-phimosis-ptosis-epicanthus 
inversus syndrome)
  (1) Gonadal dysgenesis (1) NR5A1 (9q33.3) 612964 (AD)
  (2) Ovotesticular DSD (2) NR5A1 (9q33.3) (p.
Arg92Trp)
617480 (AD)
  (3) Testicular DSD (3) NR5A1 (p.Arg92Trp)
 Gonadal dysgenesis NUP107 (12q15) 607617 (AR) (described in consanguineous family; other 
phenotypes with nephrotic syndrome)
 Ovotesticular DSD RSPO1 (1p34.3) 610644 (AR) (palmoplantar hyperkeratosis, squamous cell 
carcinoma of skin)
  (1) Ovotesticular DSD SOX3 (Xq27.1) 313430 (XL:dup)
  (2) Testicular DSD
  (1) Ovotesticular DSD SOX9 (17q24.3) 278850 (AD:dup)
  (2) Testicular DSD
 Ovotesticular DSD or testicular DSD SOX10 (22q13.1) 609136 (AD:dup) (Waardenberg and Hirschsprung syndromes, 
peripheral neuropathy)
  (1) Ovotesticular DSD SRY (Yp11.2) 400045 (T)
  (2) Testicular DSD
  (1) Ovotesticular DSD WNT4 (1p36.12) 158330 (AD)
  (2) Testicular DSD 611812 (AR): SERKAL (sex reversal dysgenesis of kidneys, 
adrenals and lung) syndrome, lethal when biallelic
2. 46,XY with disorders of gonadal development: gonadal dysgenesis (GD), complete or partial (C/P-GD)
 P-GD ARX (Xp21.3) 300215 (XL:D) (Lissencephaly, epilepsy, intellectual deficiency)
 P-GD ATRX (Xq21.1) 300032 (D:del) (intellectual deficiency, α-thalassemia)
 Ovaries or C-GD CBX2 (17q25.3) 613080 (AR)
 C-GD or P-GD DAX1 (NR0B1) (Xp.21) 300018 (XL:dup)
 C-GD or P-GD DHH (12q13.12) 233420/607080 (AR/AD) (minifascicular neuropathy)
 C-GD or P-GD DMRT1 (9p24.3) 602424 (AD:del) (with or without intellectual deficiency)
 P-GD EMX2 (10q26.11) 600035 (AD:del) (intellectual deficiency, kidney agenesis)
 C-GD or P-GD ESR2 (14q23.2–q23.3) 601663 (biallelic and monoallelic)
 C-GD or P-GD FGFR2 (10q26.13) 176943 (AD) (cranyosinostosis)
 C-GD or P-GD GATA4 (8p23.1) 615542 (AD) (with or without congenital heart disease)
 C-GD HHAT (1q32.2) 605743 (AR) (single familial case description) (short stature, 
generalised chondrodysplasia, muscle hypertophy, myopia, 
intellectual deficiency)
 C-GD or P-GD MAP3K1 (MEKK1) (5q11.2) 613762 (AD)
 C-GD or P-GD NR5A1 (9q33.3) 612965 (AD)/(AR) (rarely primary adrenal failure, 
hypogonadotropic hypogonadism) 
 C-GD or P-GD SOX9 (17q24.3) 114290 (AD) (campomelic dysplasia)
 C-GD or P-GD SRY (Yp11.2) 400044 (D)
 C-GD or P-GD TSPYL1 (6q22.1) 608800 (AR) (sudden infant death with dysgenesis of the 
testes, SIDDT syndrome)
 Ovaries or ovotesticular DSD or 
C-GD
WNT4 (1p36.12) 603490 (AD:dup)
607102 (AD)
 P-GD WT1 (11p.13) (1) 194072 (del 11.p13: WAGR syndrome)
(2) 194080 (inactivation: Denys-Drash syndrome)
(3) 136680 (splicing: Frasier syndrome)
 C-GD or P-GD or ovotesticular DSD ZFPM2 (FOG2) (8q23.1) 616067 (AD) (with or without congenital heart disease)
 C-GD or P-GD ZNRF3 (22q12.1) 612062 (AD) 
(Continued)
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Clinical diagnosis Gene (locus) OMIM (inheritance) (additional phenotype)
3. 46,XX DSD with androgen excess
 CAH with 3β-hydroxysteroid dehydrogenase 
type 2 deficiency
HSD3B2 (1p12) 201810 (AR) (adrenal and gonadal deficiency)
 CAH with 21-hydroxylase deficiency CYP21A2 (6p21.33) 201910 (AR) (adrenal deficiency)
 CAH with 11β-hydroxylase deficiency CYP11B1 (8q24.3) 202010 (AR) (adrenal deficiency)
 P450-oxidoreductase deficiency POR (7q11.23) 201750 (AR) (antley-Bixler syndrome, 
craniosynostosis ±)
 Aromatase deficiency CYP19A1 (15q21.2) 613546 (AR) (maternal and foetal virilisation)
 Oestrogen insensitivity ESR1 (6q25.1–q25.2) 615363 (AR) (overgrowth, osteoporosis, 
polycystic ovary syndrome) 
 Glucocorticoid insensitivity GRα (NR3C1) 5q31.3 615962 (AD) (hypertension)
4. 46,XY DSD with abnormal androgen synthesis or action or isolated hypospadias or cryptorchidism
 Abnormal LH LHB (19q13.33) 228300 (AR) (bioinactive LH)
 LH/CG insensitivity LHCGR (2p16.3) 238320 (AR) (Leydig cell aplasia, hypoplasia)
 7-Dehydro-cholesterol desmolase deficiency DHCR7 (11q13.4) 270400 (AR) (Smith-Lemli-Opitz syndrome)
 STAR deficiency (Lipoid CAH) STAR (8p11.23) 201710 (AR)
  (1) Classical form (1) Adrenal and gonadal deficiency
  (2) Non-classical form (2) Adrenal deficiency
 CAH with cholesterol desmolase deficiency CYP11A1 (15q24.1) 613743 (AR) (adrenal and gonadal deficiency)
 CAH with 3β-hydroxysteroid dehydrogenase 
type 2 deficiency
HSD3B2 (1p12) 201810 (AR) (adrenal and gonadal deficiency)
CYP17A1 (10q24.32) 202110 (AR)
  (1) CAH with combined 17 
hydroxylase/17,20-lyase deficiency
(1) CAH + hypertension + gonadal deficiency
  (2) Isolated 17,20-lyase deficiency (2) Gonadal deficiency
 P450-oxidoreductase deficiency POR (7q11.23) 201750 (AR) (Antley-Bixler syndrome)
 Cytochrome b5 deficiency CYB5A (18q22.3) 250790 (AR) (methemoglobinemia type IV)
 17β-Hydroxysteroid-dehydrogenase type 3 
(17-keto-reductase) deficiency
HSD17B3 (9q22.32) 264300 (AR) (Gonadal deficiency)
 5α-Reductase type 2 deficiency SRD5A2 (2p23.1) 264600 (AR)
 Backdoor steroidogenesis deficiency AKR1C2 (10p15.1) 614279 (AR)
AKR1C4 (10p15.1) DSD with DHT deficiency and apparent 17,20-
lyase deficiency + normal CYP17A1 and SRD5A2
 Androgen insensitivity:
 Complete (CAIS)
 Partial (PAIS)
AR (Xq12) 300068/312300/300633 (XL)
 X-linked hypospadias MAMLD1 (CXOrf6) (Xq28) 300758 (XL) (hypospadias)
 Isolated hypospadias ATF3 (1q32.3) 603148 (AD ??)
 Cryptorchidism INSL3 (19p13.11) 219050 (AD)
 Cryptorchidism RXFP2 (LGR8/GREAT/GPR106) 
(13q13.1)
606655 (AD ??)
5. 46,XY DSD with abnormal anti-Müllerian hormone secretion or action
 Persistent Müllerian duct syndrome type I AMH (19p13.3) 261550 (AR)
 Persistent Müllerian duct syndrome type II AMHR2 (12q13.13) 261550 (AR)
6. 46,XX DSD with Müllerian duct abnormalities
 MURCS (Müllerian Aplasia, Renal aplasia, 
Cervico-thoracic somite abnormalities) 
syndrome
multigenic 601076
 MRKH (Mayer-Rokitansky-Küster-Hauser) 
syndrome, types I and II
CNV at 17q12, 1q21.1, 
22q11.21, Xq21.31
277000
 Müllerian Aplasia and hyperandrogenism WNT4 (1p36.12) 158330 (AD)
 Hand-foot-uterus syndrome HOXA13 (7p15.2) 140000 (AD)
??, unknown; AD, autosomal dominant; AR, autosomal recessive; CAH, congenital adrenal hyperplasia; C-GD, complete gonadal dysgenesis; CNV, copy 
number variation; D, dominant; Del, deletion; DSD, different sex development; Dup, duplication; P-GD, partial gonadal dysgenesis; T, translocation; XL, 
X-linked.
Table 1 Continued.
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biochemistry, genetics, radiology, occasionally pathology) 
should be able to provide knowledge and technologies 
that could help in clarifying the possible genetic causes 
(Fig.  1). For this, the chromosomal sex should be 
determined at the outset because this is the basis for 
assignment of a DSD case to one of the three major DSD 
subclasses according to established DSD classification (19). 
Depending on this, the clinical phenotype, the hormonal 
constellation, the family history of DSD and the presence 
or absence of consanguinity, a molecular diagnosis will 
be sought by using the most adequate molecular testing.
Chromosomal sex
Besides careful clinical evaluation of the patient with DSD, 
first-line investigation of an individual with DSD involves 
confirming the chromosomal sex using quantitative 
fluorescence polymerase chain reaction (QFPCR) and 
karyotype. QFPCR detects a series of markers on the sex 
chromosomes and has a turn-around time of 1–2  days. 
This technique has largely replaced fluorescence in situ 
hybridisation. The analysis of karyotype is a cytogenetic 
technique (involving G-banding) and is essential in 
the initial classification of any DSD into one of three 
categories: sex chromosome DSD, 46,XX DSD or 46,XY 
DSD. In some centres karyotyping has been replaced by 
array-comparative genomic hybridisation (aCGH) or SNP 
array, with much faster turn-around times than G-banding 
of 5–10 days. Unlike karyotype these techniques will not 
detect structural chromosomal rearrangements and may 
be less effective at detecting sex chromosome mosaicism. 
If sex chromosome DSD is identified no further genetic 
analysis is required. Details on different types of sex 
chromosomal DSDs and testing methods have been 
published (9).
A DSD may be suspected in the prenatal period based 
on family history or on the foetal genital ultrasound 
(US) appearance that may be discordant with the foetal 
genetic sex. An urgent genetic diagnosis is required if the 
parents consider pregnancy interruption (depending on 
the country’s legislation, the aetiology and the weeks of 
gestation). The first approach is to determine the foetal 
genetic sex. Non-invasive prenatal diagnosis (NIPD) can 
identify Y chromosome-specific markers (one within the 
SRY gene) using QFPCR in maternal peripheral blood 
cell-free foetal DNA from the 6th week (21), but most 
diagnostic laboratories recommend maternal blood 
sample collection from 7  weeks. If this technique is 
unavailable, the presence of SRY, the karyotype and the 
carrier status of a known genetically determined DSD 
condition can be investigated on a chorionic villus biopsy 
(from 9th to 11th weeks) or in amniotic fluid cells (from 
15 to 20 weeks). Nowadays, the preferred approach is by 
NIPD and should be sought in collaboration with centres 
offering this test as this is not associated with risk of 
termination of pregnancy and as it can be performed at 
earlier gestational ages.
Copy number variation analysis
Higher resolution chromosome analysis through aCGH 
or SNP array allows the detection of microduplications 
or microdeletions below the threshold of a standard 
karyotype (<5 Mb). In some centres, aCGH has replaced 
the traditional karyotype but in others aCGH or SNP array 
is used as part of second-line investigations for DSD in 
the presence of associated malformations or other system 
involvement. CNVs may be present in one-fifth of DSD 
cases, although they are more prevalent in syndromic 
forms (22, 23, 24). Indeed, several genes regulating sex 
development have been shown to exert a dose-dependent 
effect such as duplications of FGF9, SOX3 or SOX9 in 
46,XX DSD and of DAX1 or WNT4 in 46,XY DSD as well 
as deletions of ATRX, DMRT1, EMX2 or WT1 in 46,XY 
DSD (Table 1). Alterations in gene dosage may be detected 
by multiplex ligation-dependent probe amplification 
(MLPA), SNP array or aCGH: MLPA is designed to detect 
intragenic and whole gene CNV in specific target sites 
while aCGH is able to detect CNV along the genome. In 
general SNP array can detect smaller regions of CNV than 
other more dated platforms, such as oligo-aCGH. These 
techniques may detect intragenic deletions that may not 
Figure 1
Diagnostic approaches to differences/disorders of sex 
development (DSD). (A) The traditional pathway approaches 
the diagnosis in a stepwise stratification. In particular, 
targeted genetic test are often only performed after 
biochemical guidance. (B) The recommended multidisciplinary 
approach in which the information on clinical phenotyping is 
considered in parallel with the biochemical (hormonal) data 
and genetic results (the karyotype and the candidate gene 
results) in an integrative manner.
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always be detected by Sanger sequencing of genes (22, 25, 
26, 27). CNVs have been reported to be present in one-
third of children with DSD (21) and, although in this 
report three quarters were classified as being of uncertain 
clinical significance, upon review, half of these had in 
fact been reported in association with DSD (28). This 
highlights the importance of diagnostic services being 
adequately resourced to interpret genetic findings as well 
as the need for collaboration and data sharing to facilitate 
the interpretation of these often challenging results (28).
In addition, WES has the potential to detect CNVs in 
the coding regions of genes at an exon-level resolution, 
and this is not always feasible when using aCGH or MLPA. 
In the near future, WGS will be able to detect CNVs in 
non-coding regulatory regions (29).
Sanger sequencing
Sanger sequencing of exonic coding, flanking regions 
and sometimes of other regions of interest (i.e. promoter 
regions) of a candidate gene could be performed in:
– Targeted (hypothesis-driven) sequencing of known 
DSD genes following meaningful clinical and 
hormonal assessment (e.g., CYP21A2, CYP11B1, 
SRD5A2, HSD17B3, AR and others) (30).
– Targeted (hypothesis-driven) sequencing of known 
DSD genes in which HTS methods are currently difficult 
to interpret due to complex gene rearrangements, 
deletions, etc. (e.g., CYP21A2).
– Sanger sequencing to segregate a specific gene variant 
in a family.
– Validation of newly set up HTS methods in diagnostic 
laboratories (DSD panels, WES, WGS) as part of 
laboratory quality management.
– Validation of HTS data in single cases and their relatives, 
if necessary based on laboratory quality management.
Individual gene sequencing is increasingly being replaced 
by HTS of candidate genes or exome, even when clinical 
and biochemical phenotypes point to a specific gene 
and based on local and national provision of diagnostic 
pathways.
HTS techniques
Due to the highly variable aetiology of DSD, a large 
number of genes can be considered causative. Moreover, 
the clinical appearance and the hormonal patterns are 
often variable, hampering classical hypothesis-driven 
prediction of a likely causative gene in DSD. Therefore, 
HTS-based strategies are increasingly replacing traditional 
sequencing methods, which are laborious and can only 
analyse one gene at the time. A panel of candidate genes 
with a robust coverage of all genomic regions of interest is 
increasingly regarded as the first-tier approach. However, 
the authors of this COST Action remind the readership that, 
with the only exception of certain disruptive mutations in 
some (but not all) DSD-related genes (e.g., the androgen 
receptor gene and a few more), molecular diagnosis 
cannot reliably predict the functional consequences for 
an individual DSD case (e.g., the potential of steroid 
biosynthesis by the gonads or by the adrenals or the 
sensitivity to sex steroids), which are important aspects 
for individualised clinical management.
HTS technologies are continuously improving and the 
pure technical costs per base are significantly decreasing. 
However, this does not take into account the increased 
need for bioinformatic expertise. The specialist resources 
that are required for multidisciplinary interpretation, 
explanation and counselling of data following exome 
or genome sequencing will also need to be taken into 
account when considering overall costs. The strategy 
for selecting the best HTS approach will depend on the 
number of genes on a selected panel, gene coverage and 
local availability. Strategies for the stepwise molecular 
investigation of a DSD have been described (8, 31). It is 
likely that these HTS strategies will further evolve in the 
near future, based on continuous technical advances. 
WES-based HTS strategies are more flexible than panel-
based HTS strategies and allow the identification of new 
DSD-related genes. However, the service laboratories 
and clinicians need to be aware of problems associated 
when detecting variants of unknown significance (VUS). 
Increasing experience with HTS techniques suggests that 
in suspected 46,XY DSD, the identification of CNVs 
and single gene variants does not always correlate with 
endocrine profiling (28). Altogether, this may change the 
classical sequential diagnostic pathway in DSD, favouring 
a more parallel approach involving integration of both 
biochemical (hormonal) and genetic (HTS-related) 
testing, starting with the initial evaluation of the patient 
(5, 32). As stated earlier, genetic testing and hormonal 
diagnosis must be considered complementary in DSD. 
To allow better understanding of DSDs and, hence, 
improved diagnostic algorithm in the future, this COST 
Action strongly recommends that molecular data together 
with clinical and biochemical data in DSDs should be 
prospectively collected in international databases like 
I-DSD Registry (33). The I-DSD Registry (www.i-dsd.org) 
currently has a facility to act as a secure repository for 
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detailed genetic data. Alternatively, this registry can also 
act as a facility that can signpost investigators to data held 
in other local repositories.
The experience of different authors reporting results 
obtained with candidate gene panels designed to analyse 
a variable number of genes associated with DSD (both 
46,XY and 46,XX and even with hypogonadotropic 
hypogonadism) varies according to panel content and 
selected patient series (34, 35, 36, 37, 38). An overview of 
all genes included in at least one of recently reported large 
DSD gene panels is given in Cools et al (19).
A WES first-line approach would require a much more 
thorough bioinformatic analysis and may result in a lower 
guarantee of coverage, thus increasing the possibility 
of missing variants in a DSD candidate gene. However, 
many clinical services will probably increase its use as a 
first-line approach, provided that prices progressively fall, 
quality further improves, technical hurdles be addressed 
appropriately and bioinformatic analysis speed up, thus 
facilitating the broadest view on molecular genetic 
variations found in DSD.
WES has afforded discovery of genes previously not 
associated with DSD in humans such as FOG2/ZFPM2 
(39), HHAT (40), FGFR1 (41), SOX8 (42), NR2F2 (43) and 
ZNRF3 (44) and variants in known genes in previously 
undescribed phenotypes such as for NR5A1 (1, 45, 46) or 
in previously unsuspected genes (47, 48, 49).
When AIS is highly suspected but AR gene exon coding 
and flanking region sequences are normal, whole AR gene 
and promoter regions HTS may reveal pathogenic variants 
(50). In addition, variants in other genes regulating the AR 
pathway may be suspected in the recently proposed AIS 
type II patients when ApoD expression is not upregulated 
by androgens in the patient genital skin fibroblasts (51) 
and will have to be characterised on a molecular level by 
WES or WGS.
Many of the genetic variants in DSD encode 
transcription factors such as SRY, SOX9, NR5A1, and 
FOXL2 and it can be hypothesised that, at least part of the 
missing genetic variation in severe forms of DSD, can be 
explained by non-coding variants in regulatory elements 
(52) that could be detected by WGS. As stated earlier, WES 
has the potential to detect CNVs in the coding regions 
while WGS will be able to detect CNVs in non-coding 
regulatory regions (29). In addition, WES and WGS, will 
most likely demonstrate that the phenotype of some 
individuals with DSD result from a combination of gene 
variations (oligogenic) (15, 16), although monogenic 
causes will remain for a specific set of phenotypes (i.e. 
steroid enzyme deficiencies and hormone resistance 
syndromes such as complete AIS and Leydig cell aplasia/
hypoplasia).
Existing diagnostic algorithms
A number of algorithms have been published to guide the 
genetic diagnosis of DSD, depending on available clinical 
data, chromosomal sex, initial hormonal evaluation, 
presence of associated malformations, functioning 
testes or Müllerian structures, family history of DSD 
or reproductive problems and preferred or available 
local genomic approach. The most general approaches 
are presented by Croft et  al. (7) and Alhomaidah et  al. 
(5). Their paradigms begin with a DSD phenotype 
considering the physical features, hormone findings 
and confirmation of sex chromosome complement, 
followed by either a targeted gene panel approach or a 
broad approach involving WES or WGS, the genomic 
outcomes of each pathway and the consequences for the 
patients. More detailed algorithms determine suitability 
for extensive testing through WES or WGS (31) by 
considering the presence of associated malformations, the 
results of a-CGH and sex chromosomes, the presence of 
functioning testes or Müllerian structures, the gene panel 
results and the presence of a family history. A practical 
approach in infants with atypical genitalia considers the 
presence of palpable gonads, the anatomy of the external 
genitalia, the presence of uterus and the karyotype 
which guide further chromosomal analyses, hormonal 
evaluation and genomic testing (9). The most detailed 
pathway for investigating 46,XY DSD cases without sex 
chromosome rearrangement requires a multidisciplinary 
team diagnostic assessment (clinical endocrinology, 
biochemistry, clinical genetics and molecular genetics), 
the results of a XY DSD candidate gene panel or of a WES/
WGS approach and the need for second-line endocrine 
tests and functional analyses (in silico and/or in vitro) to 
facilitate the interpretation of VUS (5).
The majority of accredited laboratories follow the 
American College of Medical Genetics and Genomics 
(ACMG) guidelines for the interpretation of sequence 
variants and use specific standard terminology (such as 
‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, 
‘likely benign’ and ‘benign’) to describe variants identified 
in genes that cause Mendelian disorders (53). At present, 
the general recommendation is to report variants 
classified as ‘pathogenic’, ‘likely pathogenic’ and of 
‘uncertain significance’ in gene(s) related to the patient 
phenotype, while variants detected by clinical exome and 
genome sequencing in unrelated genes will be reported 
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as secondary findings (54, 55). With generation of more 
robust genomic data in this field, these guidelines will 
evolve as the relationship between the genotype and the 
phenotype becomes increasingly coherent.
Recommendations for the genetic 
molecular diagnosis of DSD
The karyotype will first determine the subgroup of DSD, 
either chromosomal sex DSD, 46,XX or 46,XY.
A CNV analysis should be added to the first-line 
diagnostics in both 46,XX and 46,XY, especially if the 
phenotype includes malformations in other systems in 
addition to those involved in urogenital development.
All neonates and young babies presenting with DSD 
need comprehensive steroid analysis in order to avoid 
missing a potentially life-threatening acute adrenal 
insufficiency (e.g. in 46,XY DSD due to StAR or P450scc 
deficiencies, as well as in 46,XX DSD and a virilising 
form of CAH such as 21-hydroxylase, 11ß-hydroxylase 
or 3ß-hydroxysteroid dehydrogenase deficiencies) (20). A 
specific steroid profile in urine and/or plasma may rapidly 
lead to a likely DSD target gene that can be sequenced on 
a hypothesis-driven basis by Sanger sequencing or by HTS.
In all other cases, the multidisciplinary team should 
conduct the physical phenotyping and biochemical 
(hormonal) evaluation in parallel with the genetic study 
(Fig. 1). Except for confirming a monogenic familial DSD 
cause, a HTS panel of candidate genes or WES should 
be used preferably to analyse candidate genes. WGS is 
currently reserved for the characterisation of novel DSD 
genes or in cases with a suspected oligogenic/polygenic 
basis of the DSD.
These recommendations are based on currently 
available knowledge and technologies and are to be 
considered by the professionals and the Health System 
Organisations on a country-by-country basis. The 
European Union has recently launched the coordination 
of reference centres for rare endocrine diseases (Endo-
ERN), with the aim of contributing to the availability of 
adequate patient management. Each country or region 
should organise the availability of genetic diagnoses 
following recommendations by multidisciplinary teams 
for each group of rare diseases. It is evident that both the 
professionals and the affected persons suffer inequalities: 
many world countries or regions lack resources to perform 
even the most basic analyses; even in countries with 
sufficient resources, a variable percentage of persons lack 
access to medical attention.
Genetic information and molecular data, together 
with phenotypic, biochemical and outcome data 
(when available) in DSDs, should be accessible through 
international databases like the I-DSD and I-CAH 
Registries. Databases are important for improving patient 
care and expanding knowledge about the process of sex 
determination and development.
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